Year: 2023
Type: article
Abstract: The 2022 Immunotherapy Bridge congress (November 30-December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy. As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate.
Institutions: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Roswell Park Comprehensive Cancer Center, Georgetown University, University of Chicago Medicine Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Providence Portland Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,490
Funder: National Cancer Institute
Awards: Resistance To Targeted Immunotherapies:CART19 as a Paradigm, Resistance To Targeted Immunotherapies:CART19 as a Paradigm, MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER, Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
OpenAlex ID: W4366769401